Some statistical considerations in the clinical development of cancer immunotherapies
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Some statistical considerations in the clinical development of cancer immunotherapies
Authors
Keywords
-
Journal
PHARMACEUTICAL STATISTICS
Volume 17, Issue 1, Pages 49-60
Publisher
Wiley
Online
2017-11-03
DOI
10.1002/pst.1835
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Dose Finding of Small-Molecule Oncology Drugs: Optimization throughout the Development Life Cycle
- (2016) P. A. Ja nne et al. CLINICAL CANCER RESEARCH
- Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab
- (2016) F. Stephen Hodi et al. JOURNAL OF CLINICAL ONCOLOGY
- Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
- (2016) Arlene Chan et al. LANCET ONCOLOGY
- The Net Chance of a Longer Survival as a Patient-Oriented Measure of Treatment Benefit in Randomized Clinical Trials
- (2016) Julien Péron et al. JAMA Oncology
- On the restricted mean survival time curve in survival analysis
- (2015) Lihui Zhao et al. BIOMETRICS
- 2015 Guidance on cancer immunotherapy development in early-phase clinical studies
- (2015) et al. CANCER SCIENCE
- Milestone Survival: A Potential Intermediate Endpoint for Immune Checkpoint Inhibitors
- (2015) Tai-Tsang Chen JNCI-Journal of the National Cancer Institute
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- A product of independent beta probabilities dose escalation design for dual-agent phase I trials
- (2015) Adrian P. Mander et al. STATISTICS IN MEDICINE
- A versatile test for equality of two survival functions based on weighted differences of Kaplan-Meier curves
- (2015) Hajime Uno et al. STATISTICS IN MEDICINE
- Milestone Survival: A Potential Intermediate Endpoint for Immune Checkpoint Inhibitors
- (2015) Tai-Tsang Chen JNCI-Journal of the National Cancer Institute
- Time-to-event continual reassessment method incorporating treatment cycle information with application to an oncology phase I trial
- (2014) Bo Huang et al. BIOMETRICAL JOURNAL
- Moving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival Analysis
- (2014) Hajime Uno et al. JOURNAL OF CLINICAL ONCOLOGY
- Optimal Designs With Interim Analyses for Randomized Studies With Long-Term Time-Specific Endpoints
- (2014) Bo Huang et al. Statistics in Biopharmaceutical Research
- Bayesian data augmentation dose finding with continual reassessment method and delayed toxicity
- (2013) Suyu Liu et al. Annals of Applied Statistics
- Predicting the restricted mean event time with the subject's baseline covariates in survival analysis
- (2013) L. Tian et al. BIOSTATISTICS
- Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma
- (2013) Antoni Ribas et al. JOURNAL OF CLINICAL ONCOLOGY
- Adaptive designs for dual-agent phase I dose-escalation studies
- (2013) Jennifer A. Harrington et al. Nature Reviews Clinical Oncology
- Adjusting overall survival for treatment switches: commonly used methods and practical application
- (2013) Claire Watkins et al. PHARMACEUTICAL STATISTICS
- Statistical issues and challenges in immuno-oncology
- (2013) Tai-Tsang Chen Journal for ImmunoTherapy of Cancer
- Using the time-to-event continual reassessment method in the presence of partial orders
- (2012) Nolan A. Wages et al. STATISTICS IN MEDICINE
- Continual Reassessment Method for Partial Ordering
- (2011) Nolan A. Wages et al. BIOMETRICS
- Robust EM Continual Reassessment Method in Oncology Dose Finding
- (2011) Ying Yuan et al. JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION
- Dose-finding approach for dose escalation with overdose control considering incomplete observations
- (2011) A. Mauguen et al. STATISTICS IN MEDICINE
- The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt
- (2011) Patrick Royston et al. STATISTICS IN MEDICINE
- Improved Endpoints for Cancer Immunotherapy Trials
- (2010) A. Hoos et al. JNCI-Journal of the National Cancer Institute
- Generalized pairwise comparisons of prioritized outcomes in the two-sample problem
- (2010) Marc Buyse STATISTICS IN MEDICINE
- Optimal Two-Stage Phase II Designs with Long-Term Endpoints
- (2010) Bo Huang et al. Statistics in Biopharmaceutical Research
- A Latent Contingency Table Approach to Dose Finding for Combinations of Two Agents
- (2008) Guosheng Yin et al. BIOMETRICS
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now